Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Latest Upgrades and Downgrades: Wynn, Honeywell, Apple
By Rob Lenihan
Apr 9, 2021 2:55 PM EDT
INVESTING
Latest Upgrades and Downgrades: Wynn, Honeywell, Apple
By Rob Lenihan
Apr 9, 2021 2:55 PM EDT
INVESTING
Oncternal Therapeutics Jumps on Bullish Oppenheimer Initiation
By Tony Owusu
Apr 7, 2021 4:05 PM EDT
PRESS RELEASES
Oncternal Therapeutics To Report Fourth Quarter 2020 Financial Results And Provide Business Update
By GlobeNewswire
Mar 4, 2021 8:00 AM EST
PRESS RELEASES
Oncternal Therapeutics Reports Granting Of An Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
By GlobeNewswire
Feb 22, 2021 5:33 PM EST
PRESS RELEASES
Oncternal Therapeutics Announces The Appointment Of Dr. Rosemary Mazanet To The Board Of Directors
By GlobeNewswire
Jan 28, 2021 4:01 PM EST
PRESS RELEASES
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. To Manufacture Lentiviral Vectors For Its ROR1-targeting CAR-T Cell Therapy Program
By GlobeNewswire
Jan 14, 2021 8:00 AM EST
PRESS RELEASES
Oncternal Therapeutics And Karolinska Institutet Establish Collaboration For Research And Development Of ROR1-targeting CAR-T And CAR-NK Cell Therapies
By GlobeNewswire
Jan 7, 2021 4:01 PM EST
PRESS RELEASES
Oncternal Therapeutics Announces Closing Of $86.2 Million Bought Deal And Full Exercise Of Option To Purchase Additional Shares
By GlobeNewswire
Dec 14, 2020 4:01 PM EST
PRESS RELEASES
Oncternal Therapeutics Increases Previously Announced Bought Deal To $75.0 Million
By GlobeNewswire
Dec 9, 2020 11:50 PM EST
PRESS RELEASES
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
By GlobeNewswire
Dec 9, 2020 6:07 PM EST
PRESS RELEASES
Oncternal Therapeutics Increases Previously Announced Bought Deal To $22.5 Million
By GlobeNewswire
Nov 17, 2020 11:00 PM EST
PRESS RELEASES
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
By GlobeNewswire
Nov 17, 2020 5:27 PM EST
PRESS RELEASES
Oncternal Therapeutics Announces Presentation Of Interim Phase 1 Clinical Trial Data For TK216 In Patients With Relapsed/Refractory Ewing Sarcoma At CTOS 2020 Virtual Annual Meeting
By GlobeNewswire
Nov 11, 2020 8:00 AM EST
PRESS RELEASES
Oncternal Therapeutics To Present At Stifel Virtual Healthcare Conference
By GlobeNewswire
Nov 9, 2020 4:01 PM EST
PRESS RELEASES
Milestone Pharmaceuticals Strengthens Board Of Directors With Two New Appointments
By PR Newswire
Sep 22, 2020 7:00 AM EDT
PRESS RELEASES
Oncternal Therapeutics Announces Presentation Of Interim Phase 1 Clinical Trial Data For TK216 In Patients With Relapsed/Refractory Ewing Sarcoma At ESMO Virtual Congress 2020
By Business Wire
Sep 21, 2020 8:00 AM EDT
PRESS RELEASES
Oncternal Therapeutics Increases Previously Announced Bought Deal To $4.5 Million
By Business Wire
Aug 27, 2020 9:18 PM EDT
PRESS RELEASES
Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering
By Business Wire
Aug 27, 2020 5:18 PM EDT
PRESS RELEASES
Oncternal Therapeutics To Report Second Quarter 2020 Financial Results And Provide Business Update
By Business Wire
Jul 30, 2020 8:00 AM EDT
PRESS RELEASES
Oncternal Therapeutics To Host Call On Cirmtuzumab And The Current Treatment Landscape For Mantle Cell Lymphoma
By Business Wire
Jul 27, 2020 8:00 AM EDT
PRESS RELEASES
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
By Business Wire
Jul 20, 2020 8:00 AM EDT
PRESS RELEASES
Oncternal Therapeutics Announces Increased Focus Of The Cirmtuzumab ROR1 Antibody Program On Mantle Cell Lymphoma
By Business Wire
Jun 30, 2020 7:45 AM EDT
PRESS RELEASES
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
By Business Wire
May 20, 2020 8:00 AM EDT
PRESS RELEASES
Oncternal Therapeutics To Report First Quarter 2020 Financial Results And Provide Business Update
By Business Wire
May 5, 2020 8:00 AM EDT
